Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting
Retrieved on:
Vendredi, mai 10, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Patient, Cell, Pharmacokinetics, KLK5, Staphylococcus epidermidis, Protein, Trial of the century, Skin, Safety, CFU, KLK, Gene, Biomarker, GLP, Society, Toxicology, Netherton syndrome, KLK7, LEKTI, Annual general meeting, Pharmaceutical industry
The data in the two oral presentations today showcase the preclinical development of ATR-12 and the clinical study design of a Phase 1b study in Netherton syndrome patients.
Key Points:
- The data in the two oral presentations today showcase the preclinical development of ATR-12 and the clinical study design of a Phase 1b study in Netherton syndrome patients.
- Additionally, in human ex vivo Netherton syndrome models, ATR-12 supernatant reduces protease activity nearly 7-fold to levels comparable to healthy skin.
- The oral presentation entitled “Staphylococcus epidermidis Strain Expressing LEKTI-D6 (ATR-12) for Netherton Syndrome” also provides the study design for an active clinical trial of ATR-12 in Netherton syndrome patients.
- “These data show the robust preclinical activity of ATR-12 in Netherton syndrome models and further supports the rationale behind our Phase 1b clinical trial in Netherton syndrome patients.”